Skip to content
Article Rich – Lifestyle
Author:
Certara
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
August 18, 2026
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
August 4, 2026
Certara Reports Second Quarter 2026 Financial Results
August 4, 2026
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
July 15, 2026
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
July 7, 2026
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
June 22, 2026
Certara Announces CFO Transition
June 17, 2026
Genprex to Participate at BIO International Convention 2026
June 17, 2026
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
May 26, 2026
Certara to Participate in Upcoming Investor Conferences
May 21, 2026
1
2
3
Next Page
→